Boothbay Fund Management LLC Sells 29,362 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Boothbay Fund Management LLC decreased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 27.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,865 shares of the biopharmaceutical company’s stock after selling 29,362 shares during the period. Boothbay Fund Management LLC’s holdings in Catalyst Pharmaceuticals were worth $1,604,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of CPRX. Barclays PLC boosted its holdings in Catalyst Pharmaceuticals by 129.4% in the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock worth $4,939,000 after buying an additional 140,129 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 3.4% in the 3rd quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company’s stock worth $1,221,000 after purchasing an additional 1,967 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after purchasing an additional 33,888 shares during the period. CWA Asset Management Group LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 25.5% in the 4th quarter. CWA Asset Management Group LLC now owns 33,698 shares of the biopharmaceutical company’s stock worth $703,000 after purchasing an additional 6,853 shares during the period. Finally, Oliver Luxxe Assets LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 103.5% in the 4th quarter. Oliver Luxxe Assets LLC now owns 69,250 shares of the biopharmaceutical company’s stock worth $1,445,000 after purchasing an additional 35,225 shares during the period. Institutional investors own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Robert W. Baird lifted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $32.29.

Catalyst Pharmaceuticals Trading Up 0.8 %

Shares of CPRX stock opened at $23.63 on Tuesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of 20.03, a P/E/G ratio of 3.31 and a beta of 0.79. The stock has a fifty day simple moving average of $22.60 and a two-hundred day simple moving average of $22.24.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.